IBB250110P160000
- 23.80
- 0.000.00%
iShares Biotechnology ETF Newsroom
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Merck Downgraded by Truist to Hold Over Growth Concerns
Sector Update: Health Care Stocks Rise Premarket Wednesday
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of FOMC Meeting Minutes
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Amgen Analyst Ratings
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Looking Into Gilead Sciences's Recent Short Interest
Vertex Grapples With Bearish Chart As Death Cross Emerges
Alnylam Pharmaceuticals Analyst Ratings